CTOs on the Move


 
We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinsahealth.com
  • 535 Mission St 18th Floor
    San Francisco, CA USA 94105
  • Phone: 415.236.4811

Executives

Name Title Contact Details

Funding

Kinsa raised $17M on 03/08/2017

Similar Companies

Storandt Pann Margolis

Storandt Pann Margolis is a La Grange, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monroe Clinic and Hospital

Monroe Clinic and Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Monroe Clinic and Hospital is based in Monroe, WI. You can find more information on Monroe Clinic and Hospital at www.monroeclinic.org

Advanced Therapies

Accelerating progress and time to market of biopharmaceuticals with our integrated CDMO and Testing Service Platform. Global HQ in Philadelphia, PA.

Southwest Transplant Alliance

For more than 40 years, Southwest Transplant Alliance (STA) has been saving lives by recovering donated organs for individuals awaiting a life-saving transplant. STA is among the largest of 58 federally designated, non-profit organ procurement organizations. The organization serves communities in 94 counties throughout Texas including North Texas, Beaumont, Bryan/College Station, Corpus Christi, El Paso, Galveston, Midland/Odessa, Temple and Tyler.

Halberd Corporation

Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.